Evidence map›Paper›PMID 32921708›Full record

ArticleActa bio-medica : Atenei Parmensis2020

Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study.

Ashraf T Soliman, Arun Prabhakaran Nair, Muna S Al Masalamani, Vincenzo De Sanctis, Mohamad A Abu Khattab, Arwa E Alsaud, Sreethish Sasi, Elrazi A Ali, Hassan Ola A, Fatima M Iqbal and 4 more

Abstract readComparative StudyMulticenter Study
In one paragraph

Article in Acta bio-medica : Atenei Parmensis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ashraf T SolimanPediatric and Endocrinology, Hamad General Hospital, Doha, Qatar . Atsoliman@yahoo.com.
Arun Prabhakaran NairCommunicable Disease Center (CDC), Hamad Medical Corporation (HMC), Doha, Qatar. anair9@hamad.qa.
Muna S Al MasalamaniCommunicable Disease Center (CDC), Hamad Medical Corporation (HMC), Doha, Qatar. MALMASLAMANI@hamad.qa.
Vincenzo De SanctisQuisisana Hospital, Ferrara. vdesanctis@libero.it.
Mohamad A Abu KhattabCommunicable Disease Center (CDC), Hamad Medical Corporation (HMC), Doha, Qatar. MABUKHATTAB@hamad.qa.
Arwa E AlsaudDepartment of Endocrinology and Diabetes, Hamad Medical Corporation (HMC), Doha, Qatar. arwa.alsaud@gmail.com.
Sreethish SasiInternal Medicine Dept., Hamad General Hospital (HGH), Hamad Medical Corporation (HMC), Doha, Qatar. SSasi7@hamad.qa.
Elrazi A AliInternal Medicine Dept., Hamad Medical Corporation (HMC), Doha, Qatar. EAli14@hamad.qa.
Hassan Ola AMedical Resident, Family Medicine, Medical Education, Hamad Medical Corporation (HMC), Doha, Qatar. ola.gornass@hotmail.com.
Fatima M IqbalInfectious Diseases, Communicable Disease Center (CDC), Hamad Medical Corporation (HMC), Doha, Qatar. fiqbal1@hamad.qa.
Abdulqadir J NashwanHazm Mebaireek General Hospital (HMGH), Hamad Medical Corporation (HMC), Doha, Qatar. anashwan@hamad.qa.
Jesin FahadQuality Management Data Analyst, Communicable Disease Center (CDC), Hamad Medical Corporation (HMC), Doha, Qatar. Jesyfax@gmail.com.
Ihab El MadhounAlWakra Hospital, Hamad Medical Center. ielmadhoun@hamad.qa.
Mohamed A YassinNational Center for Cancer care and Research, Doha, Qatar. . yassinmoha@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is a scarcity of data regarding the effect of Type 2 diabetes mellitus (T2DM) and associated comorbidities on the clinical presentation and outcome of symptomatic patients with -COVID-19 infection in comparison with non-diabetic patients. AIM OF THE STUDY: We described and compared the clinical presentation and radiological and hematological data of a cohort of symptomatic COVID19 positive T2DM diabetic patients (n = 59) versus another cohort of non-diabetic symptomatic COVID19 positive patients (n =244) diagnosed at the same time from January 2020 to May 2020. Associated comorbidities were -assessed, and the Charlson Comorbidity Index was calculated. The outcomes including duration of hospitalization, duration of Intensive Care Unit (ICU) stay, duration of mechanical ventilation, and duration of O2 -supplementation were assessed.

resultsPrevalence of T2DM in symptomatic COVID19 positive patients was 59/303 (=19.5%).  Diabetic patients had higher prevalence of hypertension, chronic kidney disease (CKD) and cardiac dysfunction [coronary heart disease (CHD)], and congestive heart failure (CHF). Charlson Comorbidity score was significantly higher in the T2DM patients (2.4± 1.6) versus the non-diabetic -patients (0.28 ± 0.8; p: < 0.001). Clinically and radiologically, T2DM patients had significantly higher percentage of pneumonia, severe pneumonia and ARDS versus the non-diabetic patients. Hematologically, diabetic patients had significantly higher C-reactive protein (CRP), higher absolute neutrophilic count (ANC) and lower counts of lymphocytes and eosinophils compared to non-diabetic patients. They had significantly higher systolic and diastolic blood pressures, longer duration of hospitalization, ICU stay, mechanical ventilation and oxygen therapy. CRP was correlated significantly with the duration of stay in the ICU and the duration for oxygen supplementation (r = 0.37 and 0.42 respectively; p: <0.01).

conclusionsT2DM patients showed higher inflammatory response to COVID 19 with higher absolute neutrophilic count (ANC) and CRP with lower lymphocytic and eosinophilic counts. Diabetic patients had more comorbidities and more aggressive course of the disease with higher rate of ICU admission and longer need for hospitalization and oxygen use.

Indexed as

BetacoronavirusIntensive Care UnitsPandemicsAdultBiomarkersComorbidityCoronavirus InfectionsCOVID-19C-Reactive ProteinDiabetes Mellitus, Type 2FemaleFollow-Up StudiesHospitalizationHumansLeukocyte CountMaleBiomarkersC-Reactive Protein

Identifiers

PMID32921708
PMCPMC7716959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.